DGAP-News: Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
ID: 449749
25.07.2011 12:30
---------------------------------------------------------------------------
NOVATO, Calif., 2011-07-25 12:30 CEST (GLOBE NEWSWIRE) --
Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today
announced that its Phase 3 clinical trial of Delayed Release or DR Cysteamine,
known as study drug RP103 ('RP103'), for the treatment of nephropathic
cystinosis, met the primary endpoint of non-inferiority compared to Cystagon(r),
immediate-release cysteamine bitartrate. The comparison was based on white
blood cell ('WBC') cystine levels, the established efficacy surrogate biomarker
and sole primary endpoint in the clinical trial. The Company also reported that
there were no unexpected serious safety concerns experienced by patients in the
trial attributable to RP103.
Nephropathic cystinosis is a severe ultra-orphan inherited condition which
results in premature death if not treated. The current standard of care for
cystinosis is oral Cystagon(r), immediate-release cysteamine bitartrate, which
must be taken strictly every 6 hours, including a middle-of-the-night dose.
Lack of compliance with the strict dosing schedule of Cystagon(r) has been widely
reported to be a significant challenge in the therapeutic management of
cystinosis patients. RP103 is Raptor's proprietary, twice-daily formulation of
cysteamine bitartrate, designed for reduced dose frequency and improved
tolerability for the treatment of cystinosis. Raptor's pivotal Phase 3 clinical
trial was designed as an outpatient study of the pharmacodynamics,
pharmacokinetics, safety and tolerability of RP103 compared to Cystagon(r) in
cystinosis patients. The clinical trial was conducted at eight clinical
research centers in the US and Europe.
Of 41 patients who completed the Phase 3 protocol, 38 were included in the
evaluable data set, 3 not being fully compliant with the protocol. The age
range of study participants was 6-26 years, with 87% of patients below 16 years
old. On average, the peak WBC cystine level measured in patients treated with
Cystagon(r) was 0.54 +/- 0.05 nmol 1/2 cystine/mg protein, compared to an average
peak value of 0.62 +/- 0.05 nmol 1/2 cystine/mg protein for patients treated with
RP103. The mean difference was 0.08 nmol 1/2 cystine/mg protein, with a 95.8%
confidence interval of 0.00-0.16 (one sided p=0.021). As stipulated in the
Statistical Analysis Plan, the non-inferiority endpoint of the clinical trial
would be achieved when the upper end of the confidence interval around the mean
difference of WBC cystine levels did not exceed an absolute value of 0.3. The
upper end of the confidence interval in the Phase 3 clinical trial was
determined to be 0.16, thus achieving the non-inferiority endpoint.
'We are obviously very excited to have successfully met our primary endpoint of
this study,' said Christopher M. Starr, Ph.D. and CEO of Raptor, 'and we would
like to sincerely thank all the study participants, families and study
coordinators for their time and effort in helping us complete this study.'
Additionally, the endpoint was achieved at a lower average daily dose of RP103,
compared to Cystagon(r). Patients enrolled in the study were required to be 'well
controlled' under the existing Cystagon(r) therapy. The starting dose of RP103
for patientsin the Phase 3 clinical trial was initially set at 70% of their
established dose of Cystagon(r). The protocol allowed for a single RP103 dose
increase of 25%, based on intermediate WBC cystine results, to reflect the
current standard of care in establishing appropriate dosing of Cystagon(r) in
cystinosis patients. Approximately one-third of patients remained at 70% of
their starting Cystagon(r) dose throughout the study. The remaining two-thirds of
the patients had their RP103 dose increased. On average, the total daily,
steady-state dose of RP103 in patients in the Phase 3 clinical trial was 82% of
their established, incoming dose of Cystagon(r).
In the course of the study, seven serious adverse events ('SAEs') requiring a
visit to the emergency room or hospital, were reported for seven individual
patients. Of these seven SAEs, six were determined by the Principal
Investigator to be unrelated to either RP103 or Cystagon(r). One SAE, gastric
intolerance, was graded as 'possibly related' to RP103 and was subsequently
resolved. Further analyses of non-serious adverse events ('AEs') are underway
by the Company's statistical contractor.
The Company is conducting an ongoing, extension study in which all patients
completing the Phase 3 clinical trial may elect to continue on RP103 treatment
and are monitored for WBC cystine levels and safety parameters. The extension
study will provide at least six months of safety data for each patient and will
be part of Raptor's New Drug Application filing. Thirty-two patients have been
on RP103 in the extension study for at least 6 months.
Additional Successful Bioequivalence Study Announced
In a related clinical trial, Raptor demonstrated bioequivalence between RP103
administered as whole capsules and administered as capsule contents sprinkled
onto applesauce. As a significant number of cystinosis patients are too young
to take whole capsules, this result may enable the Company to expand enrollment
in the extension study to patients who are too young to swallow whole capsules
and were therefore ineligible for the pivotal Phase 3 clinical trial protocol.
In addition to the planned submission of the clinical data for publication,
Raptor will present the top line clinical data at the Canaccord Genuity Annual
Growth Conference on August 9th in Boston, MA and at the Wedbush Securities
Life Sciences Management Access Conference on August 16th in New York, NY.
About Nephropathic Cystinosis
Nephropathic cystinosis is an inborn metabolic error characterized by the
abnormal transport of cystine, an amino acid, out of the lysosomes. Poor
compliance with current treatments for nephropathic cystinosis can cause
serious health consequences, including: renal failure and resultant need for a
kidney transplant; growth failure; rickets and fractures; and photophobia and
blindness. Symptom onset typically occurs within the first year of life, when
cystine crystals accumulate in various tissues and organs, including the
kidneys, brain, liver, thyroid, pancreas, muscles and eyes.
About Cysteamine and RP103
RP103 is Raptor's proprietary enteric-coated, microbead oral formulation of
cysteamine bitartrate designed to potentially reduce dosing frequency and
reduce gastrointestinal side effects associated with immediate-release
cysteamine bitartrate, which is approved for sale by the US Food and Drug
Administration ('FDA') and the European Medicines Agency ('EMA') to treat
nephropathic cystinosis. Raptor has been granted orphan product designation for
RP103 by the EMA and FDA.
In December 2007, Raptor obtained an exclusive, worldwide license from the
University of California, San Diego for the development DR Cysteamine for
nephropathic cystinosis and cysteamine for other potential indications
including Huntington's Disease, and Non-alcoholic Steatohepatitis ('NASH').
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ('Raptor') seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis ('NASH'), Huntington's Disease ('HD'), aldehyde dehydrogenase
deficiency ('ALDH2'), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer, neurodegenerative disorders and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future results of operation or future financial
performance, including, but not limited to the following statements: that Dr
Cysteamine will reduce dose frequency and improve tolerability compared to
immediate-release cysteamine; that Raptor will file a New Drug Application, if
at all; that Raptor will be able to expand enrollment in the extension study to
patients who are too young to swallow whole capsules; that Raptor will
successfully submit the clinical data for publication, if at all; and that
Raptor will be able to successfully develop RP103 or DR Cysteamine or any of
its other product candidates. These statements are only predictions and involve
known and unknown risks, uncertainties and other factors, which may cause the
Company's actual results to be materially different from these forward-looking
statements. Factors which may significantly change or prevent the Company's
forward looking statements from fruition include: that Raptor may be
unsuccessful in developing any products or acquiring products; that Raptor's
technology may not be validated as it progresses further and its methods may
not be accepted by the scientific community; that Raptor is unable to retain or
attract key employees whose knowledge is essential to the development of its
products; that unforeseen scientific difficulties develop with the Company's
process; that Raptor's patents are not sufficient to protect essential aspects
of its technology; that competitors may invent better technology; that Raptor's
products may not work as well as hoped or worse, that the Company's products
may harm recipients; and that Raptor may not be able to raise sufficient funds
for development or working capital. As well, Raptor's products may never
develop into useful products and even if they do, they may not be approved for
sale to the public. Raptor cautions readers not to place undue reliance on any
such forward-looking statements, which speak only as of the date they were
made. Certain of these risks, uncertainties, and other factors are described in
greater detail in the Company's filings from time to time with the Securities
and Exchange Commission (the 'SEC'), which Raptor strongly urges you to read
and consider, including: Raptor's annual report on Form 10-K filed with the SEC
on November 22, 2010; and Raptor's quarterly report on Form 10-Q filed with the
SEC on July 12, 2011; all of which are available free of charge on the SEC's
web site at http://www.sec.gov. Subsequent written and oral forward-looking
statements attributable to Raptor or to persons acting on its behalf are
expressly qualified in their entirety by the cautionary statements set forth in
Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or
obligation to update any forward-looking statements.
Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser@troutgroup.com
EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo@evcgroup.com
News Source: NASDAQ OMX
25.07.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Raptor Pharmaceutical Corp.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------Unternehmensinformation / Kurzprofil:
Datum: 25.07.2011 - 12:30 Uhr
Sprache: Deutsch
News-ID 449749
Anzahl Zeichen: 13552
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 339 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis"
steht unter der journalistisch-redaktionellen Verantwortung von
Raptor Pharmaceutical Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
